Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

RedHill Biopharma (RDHL) Receivables - Net (2016 - 2025)

RedHill Biopharma has reported Receivables - Net over the past 10 years, most recently at $201000.0 for Q4 2025.

  • Quarterly Receivables - Net fell 92.08% to $201000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $201000.0 through Dec 2025, down 92.08% year-over-year, with the annual reading at $201000.0 for FY2025, 92.08% down from the prior year.
  • Receivables - Net was $201000.0 for Q4 2025 at RedHill Biopharma, down from $5.4 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $36.0 million in Q3 2022 and troughed at $201000.0 in Q4 2025.
  • The 5-year median for Receivables - Net is $23.3 million (2021), against an average of $17.8 million.
  • Year-over-year, Receivables - Net surged 1257.37% in 2021 and then crashed 92.49% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $31.7 million in 2021, then rose by 8.98% to $34.5 million in 2022, then crashed by 92.49% to $2.6 million in 2023, then fell by 2.01% to $2.5 million in 2024, then tumbled by 92.08% to $201000.0 in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Receivables - Net are $201000.0 (Q4 2025), $5.4 million (Q2 2025), and $2.5 million (Q4 2024).